Publication: Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women
Issued Date
2011-09-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-80053059560
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.94, No.9 (2011), 1019-1025
Suggested Citation
Sukanya Chaikittisilpa, Surasak Angsuwathana, Somsak Chaovisitsaree, Mayuree Jirapinyo, Kittisak Wilawan, Krasean Panyakhamlerd, Unnop Jaisamrarn, Kitirat Techatraisak, Nuntana Morakote, Charnchai Suchartwatnachai, Worapong Kongmephol, Nimit Taechakraichana Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women. Journal of the Medical Association of Thailand. Vol.94, No.9 (2011), 1019-1025. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/12364
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women
Abstract
Objectives: To investigate the efficacy and tolerability of the oral hormone replacement therapy (HRT) containing 1 mg estradiol (E2) plus 2 mg drospirenone (DRSP) in Thai women with postmenopausal symptoms. Material and Method: Fifty-five Thai women with postmenopausal symptoms participated in this multicenter, open-label, non-comparative Phase IV study. The primary endpoint was the reduction of hot flushes after 12 weeks of treatment. Secondary endpoints included changes in frequency and intensity of menopausal symptoms as well as safety assessments after 4, 8, and 12 weeks of treatment. Results: Treatment with 1 mg E2 plus 2 mg DRSP reduced the frequency of hot flushes in 94.6% of women at the end of the 12-week treatment period. In 60% of women, the frequency of hot flushes was reduced to 10% or less, compared to baseline findings and 49.1% of women had no remaining hot flushes. Other postmenopausal symptoms such as vaginal dryness, urinary incontinence, dysuria, and dyspareunia improved. The most common adverse events were vaginal bleeding or spotting and breast tenderness. Conclusion: The oral HRT of 1 mg E2 plus 2 mg DRSP was effective and well tolerated by Thai women suffering from postmenopausal symptoms.